Serous Adenocarcinoma of Ovary (DBCOND0151679)

Identifiers

Synonyms

Ovarian Serous Adenocarcinoma

Associated Data

Indicated Drugs and Targets

Not Available

Clinical Trials

Identifier	Title	Drug(s)	Purpose	Phase	Status
NCT05538624	A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary	AVB-001	treatment	1 / 2	terminated
NCT00719303	Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	No drug interventions	prevention	3	unknown_status
NCT03641287	The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors	No drug interventions	supportive_care	Not Available	terminated
NCT02016833	Development of Immunological Assays for the Evaluation of Tumor Antigen Specific Immunity	No drug interventions	Not Available	Not Available	completed
NCT01074411	Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bortezomib Bortezomib D-mannitol Carboplatin	treatment	1	completed
NCT00888615	Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Elesclomol Paclitaxel	treatment	2	completed
NCT00951496	Bevacizumab and Intravenous or Intraperitoneal Chemotherapy in Treating Patients With Stage II-III Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer	Bevacizumab Carboplatin Chloride ion Cisplatin Paclitaxel Platinum	treatment	3	completed
NCT02923739	Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Emactuzumab Paclitaxel	treatment	2	terminated
NCT01504126	Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	Propranolol	treatment	0	completed
NCT05001282	A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)	No drug interventions	treatment	1 / 2	terminated
NCT03648489	Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)	Paclitaxel Sapanisertib	treatment	2	unknown_status
NCT01097746	First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	2	completed
NCT01167712	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	3	active_not_recruiting
NCT00989651	Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Carboplatin Chloride ion Cisplatin Paclitaxel Platinum Veliparib	treatment	1	completed
NCT00565851	Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Docetaxel Gemcitabine Paclitaxel	treatment	3	active_not_recruiting
NCT00262847	Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer	Bevacizumab Carboplatin Paclitaxel	treatment	3	completed
NCT00108745	Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer	Glutamic acid Paclitaxel Paclitaxel poliglumex	treatment	3	unknown_status
NCT02101788	Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer	Doxorubicin Letrozole Paclitaxel Tamoxifen Tetracycline Topotecan Trametinib	treatment	2 / 3	active_not_recruiting
NCT02020707	Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers	Albumin human Bevacizumab Paclitaxel	treatment	1	completed
NCT05415709	Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer	Carboplatin Chloride ion Cisplatin Paclitaxel Platinum	treatment	0	recruiting
NCT02179970	To Assess the Safety of Continuous IV Administration of Plerixafor in Patients With Advanced Pancreatic, Ovarian and Colorectal Cancers	Plerixafor	treatment	1	completed
NCT05451849	A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer	Cyclophosphamide Fludarabine	treatment	1 / 2	active_not_recruiting
NCT02364713	MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer	Bevacizumab Doxorubicin Gemcitabine Measles virus vaccine live attenuated Paclitaxel Sodium iodide Tetracycline Topotecan	treatment	2	active_not_recruiting
NCT02853318	Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Bevacizumab Cyclophosphamide Pembrolizumab	treatment	2	completed
NCT04498117	Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery	Carboplatin Oregovomab Paclitaxel	treatment	3	active_not_recruiting
NCT05605535	Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer	Carboplatin Oregovomab Paclitaxel	treatment	2	recruiting
NCT04575935	Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial	No drug interventions	treatment	3	recruiting
NCT02627430	Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer	Onalespib Talazoparib	treatment	1	withdrawn
NCT01116648	Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer	Cediranib Olaparib	treatment	1 / 2	active_not_recruiting
NCT02953457	Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation	Durvalumab Olaparib Tremelimumab	treatment	2	active_not_recruiting
NCT02502266	Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer	Cediranib Doxorubicin Olaparib Paclitaxel Tetracycline Topotecan	treatment	2 / 3	active_not_recruiting
NCT02068794	MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Measles virus vaccine live attenuated Sodium iodide	treatment	1 / 2	active_not_recruiting
NCT04919629	APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion	Bevacizumab Pegcetacoplan Pembrolizumab	treatment	2	recruiting
NCT05074472	A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors	ZB131	treatment	1 / 2	completed